Enzymatica AB (FRA:EN9) Cash Flow from Operations: €-2.76 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EN9 Enzymatica AB FRA:EN9
56 GF Score
Price €0.16
GF Value €0.16
! 3 Warning Signs
View Full Analysis

What is Enzymatica AB Cash Flow from Operations?

Enzymatica AB FRA:EN9 +4.64% 56 Cash Flow from Operations is €-2.76 Mil as of Jun. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 56/100 and a GF Value™ of €0.16. The stock has 3 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2026, Enzymatica AB's Net Income From Continuing Operations was €-1.15 Mil. Its Depreciation, Depletion and Amortization was €0.00 Mil. Its Change In Working Capital was €-0.11 Mil. Its cash flow from deferred tax was €0.00 Mil. Its Cash from Discontinued Operating Activities was €0.00 Mil. Its Asset Impairment Charge was €0.00 Mil. Its Stock Based Compensation was €0.00 Mil. And its Cash Flow from Others was €0.20 Mil. In all, Enzymatica AB's Cash Flow from Operations for the three months ended in Jun. 2026 was €-1.07 Mil.


Enzymatica AB  (FRA:EN9) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Enzymatica AB's net income from continuing operations for the three months ended in Jun. 2026 was €-1.15 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Enzymatica AB's depreciation, depletion and amortization for the three months ended in Jun. 2026 was €0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Enzymatica AB's change in working capital for the three months ended in Jun. 2026 was €-0.11 Mil. It means Enzymatica AB's working capital declined by €0.11 Mil from Mar. 2026 to Jun. 2026 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Enzymatica AB's cash flow from deferred tax for the three months ended in Jun. 2026 was €0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Enzymatica AB's cash from discontinued operating Activities for the three months ended in Jun. 2026 was €0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Enzymatica AB's asset impairment charge for the three months ended in Jun. 2026 was €0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Enzymatica AB's stock based compensation for the three months ended in Jun. 2026 was €0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Enzymatica AB's cash flow from others for the three months ended in Jun. 2026 was €0.20 Mil.


Enzymatica AB Cash Flow from Operations Related Terms


Enzymatica AB Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Cash Flow from Operations Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.49 -5.87 -3.60 -5.26 -3.77

Enzymatica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.94 -1.11 0.04 -0.63 -1.07
FRA:EN9
56GF Score
Enzymatica AB FRA:EN9
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Enzymatica AB's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:

Enzymatica AB's Cash Flow from Operations for the quarter that ended in Jun. 2026 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of €-2.76 Mil mean?
Enzymatica AB (FRA:EN9) has a Cash Flow from Operations of €-2.76 Mil as of Jun. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Enzymatica AB and its competitors.
Is Enzymatica AB's Cash Flow from Operations too high?
Enzymatica AB's current Cash Flow from Operations is €-2.76 Mil. Overall, Enzymatica AB has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Cash Flow from Operations compare to ZTS?
Enzymatica AB's Cash Flow from Operations of €-2.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Drug Manufacturers company?
A good Cash Flow from Operations depends on the Drug Manufacturers industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Enzymatica AB and its competitors. Enzymatica AB's current Cash Flow from Operations is €-2.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Enzymatica AB (FRA:EN9) has a current Cash Flow from Operations of €-2.76 Mil. The stock's GF Value™ is €0.16, compared to a current price of €0.16 — trading 1.3% below its estimated fair value. The current Cash Flow from Operations is €-2.76 Mil. Enzymatica AB's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Cash Flow from Operations is €-2.76 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued. The current stock price of €0.16 is trading 1.3% below its estimated GF Value™ of €0.16.

Key valuation signals for FRA:EN9:

  • Cash Flow from Operations: €-2.76 Mil
  • GF Value™: €0.16 vs. price of €0.16 (1.3% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
56GF Score

Get the complete analysis for FRA:EN9

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.16
GF Value